Day

June 13, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study Moreau, Mateos, Berenson, Weisel, Lazzaro, Song, Dimopoulos, Huang, Zahlten-Kumeli & Stewart. Lancet Oncol, June 2018.   Background Twice a week carfilzomib at 27 mg/m² is approved for treatment of relapsed or...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand